Vincent O’Neill

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad et al. · British Journal of Cancer · 2020 · 912 citations · Full text

Medicine, Oncology, Pharmacology +13

Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Robert L. Yauch, Thomas Januario, David A. Eberhard et al. · Clinical Cancer Research · 2005 · 491 citations · Full text

Medicine, Oncology, Pharmacology +17

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Adam Brufsky, Sara A. Hurvitz, Edith A. Perez et al. · Journal of Clinical Oncology · 2011 · 419 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Roy S. Herbst, Vincent O’Neill, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2007 · 396 citations · Full text

Medicine, Oncology, Pharmacology +13

Fluorescence <i>In situ</i> Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

Fred R. Hirsch, Marileila Varella‐Garcia, Rafał Dziadziuszko et al. · Clinical Cancer Research · 2008 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17